Vancouver, British Columbia – January 26, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has commenced the diagnostic and treatment phase of its ongoing preclinical model study of autism spectrum disorder (ASD).   In this model, which is well accepted by neuroscientists, pregnant rats are exposed to valproic acid (VPA) and the resultant offspring have ASD behavioral symptoms. 

NOVA had previously identified statistically significant changes in ...

Vancouver, British Columbia – January 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has been included in the world’s first North American Psychedelic Index. Based on this index, The Horizon Psychedelic Stock Index ETF is expected to commence trading Jan. 27, 2021 under ticker “PSYK” on the NEO Exchange.

“NOVA is developing psilocybin and mushroom-based tryptamine derivatives for the treatment of autism spectrum disorder (ASD), an unmet medical need. We have started a preclinical study in a ...